Soma Pharmacy Blognews

Salix Pharma Q4 Net Loss Narrows

SomaNews — Thu, 11 Mar 2010 05:00:24 +0000

Salix Pharma Q4 Net Loss Narrows Salix Pharma has reported a net loss of $7.02m, or $0.13 per diluted share, for the fourth quarter ended December 31, 2009, compared to $11.07m, or $0.23 per diluted share, for the comparable period in 2008. Related posts:Opexa FY09 Net Loss Narrows Myriad Pharmaceuticals Q2 2009 Net Loss Narrows Down Ipsen Total Revenues [...] Related posts:

Abbott To Acquire Facet Biotech

SomaNews — Thu, 11 Mar 2010 05:00:24 +0000

Abbott To Acquire Facet Biotech Abbott has agreed to acquire Facet Biotech for $27 per share in cash for a net transaction value of approximately $450m to enhance its early- and mid-stage pharmaceutical pipeline. Related posts:Abbott Labs to pay $450 million for Facet Biotech, expand access to biotechnology drugs Euthymics Signs LOI To Acquire Dov Pharmaceutical Belgium’s Solvay sells [...] Related posts:

Nordlund Centre For Biomedical Structural Biology Purchases Maybridge Ro3 500 Fragment Library

SomaNews — Thu, 11 Mar 2010 05:00:23 +0000

Nordlund Centre For Biomedical Structural Biology Purchases Maybridge Ro3 500 Fragment Library Maybridge, a part of Thermo Fisher Scientific, has said that the Nordlund Centre for Biomedical Structural Biology (Nordlund) at Nanyang Technological University in Singapore has purchased its Ro3 500 Fragment Library. Related posts:Plans afoot for new library Inovio Biomedical highlights its advances in electroporation-delivered SynCon DNA [...] Related posts:

Eprotirome lowers LDL cholesterol up to 32% in those already on statins

SomaNews — Thu, 11 Mar 2010 05:00:22 +0000

Eprotirome lowers LDL cholesterol up to 32% in those already on statins

People whose “bad” cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar. 11, issue of the New England Journal of Medicine, Johns Hopkins and Swedish researchers say an experimental drug called eprotirome lowered cholesterol up to 32 percent in those already on statins, an effect equal to that expected from doubling the statin drug doses, without harmful side effects.

Polio immunization campaign begins across West and Central Africa

SomaNews — Thu, 11 Mar 2010 05:00:22 +0000

Polio immunization campaign begins across West and Central Africa More than 85 million children under five years old will be immunized against polio in 19 countries across West and Central Africa in a massive example of cross-border cooperation aimed at stopping a year-long polio epidemic. Related posts:WHO using new bivalent oral polio vaccine in Afghanistan Also in Global [...] Related posts:

DSPA’s lurasidone NDA accepted for FDA review

SomaNews — Thu, 11 Mar 2010 05:00:22 +0000

DSPA’s lurasidone NDA accepted for FDA review

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.

FDA clears Oculus Innovative Sciences’ Microcyn Skin and Wound HydroGel

SomaNews — Thu, 11 Mar 2010 05:00:21 +0000

FDA clears Oculus Innovative Sciences’ Microcyn Skin and Wound HydroGel

Oculus Innovative Sciences, Inc., a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn® Skin and Wound HydroGel.

Long-term use of bisphosphonates may adversely affect bone quality and increase risk of atypical fractures

SomaNews — Thu, 11 Mar 2010 05:00:21 +0000

Long-term use of bisphosphonates may adversely affect bone quality and increase risk of atypical fractures

Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

Few CE studies compare medications with nonpharmacologic interventions, and examine safety or cost-effectiveness

SomaNews — Thu, 11 Mar 2010 05:00:20 +0000

Few CE studies compare medications with nonpharmacologic interventions, and examine safety or cost-effectiveness An analysis of comparative effectiveness studies finds that few compare medications with nonpharmacologic interventions, and few examine safety or cost-effectiveness, according to a study in the March 10 issue of JAMA. Related posts:Study provides first formal analysis of comparative effectiveness research on new therapies Large [...] Related posts:

Study provides first formal analysis of comparative effectiveness research on new therapies

SomaNews — Thu, 11 Mar 2010 05:00:20 +0000

Study provides first formal analysis of comparative effectiveness research on new therapies

An analysis by researchers at the Keck School of Medicine of the University of Southern California has found that only 32 percent of medication studies published in top medical journals compare the effectiveness of existing treatments. These studies, known as comparative effectiveness studies, help doctors know which therapies work best and under what circumstances they are most effective.